Compounded Tirzepatide
The next-generation GLP-1, with dual-action results that often exceed semaglutide for tolerant patients.
Quick answer
Tirzepatide is a dual GIP and GLP-1 receptor agonist that produces stronger average weight loss than semaglutide in head-to-head trials. ZenOryva offers compounded tirzepatide prescribed by licensed clinicians, with average reductions of 20 to 22 percent of body weight over 72 weeks paired with lifestyle support.
- Active ingredient
- Tirzepatide
- Class
- GIP / GLP-1 dual receptor agonist
- Administration
- Subcutaneous injection
What it is
Tirzepatide acts on two receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. Sold under the brand names Mounjaro and Zepbound, the active ingredient is also available as a compounded preparation prescribed by licensed providers.
How it works
Hitting both GIP and GLP-1 receptors gives tirzepatide stronger appetite suppression and metabolic effects than semaglutide. Members start at a low dose and titrate every 4 weeks based on tolerance and response.
Who it's for
Adults with significant weight to lose, those who plateaued on semaglutide, or members who want the strongest available evidence-based GLP-1. Same screening criteria as semaglutide.
Benefits
- 20 to 22% average weight loss over 72 weeks in clinical trials
- Dual GIP + GLP-1 mechanism
- Often more effective for plateaus on semaglutide
- Same compounded pharmacy network and shipping
Things to consider
- Side-effect profile similar to semaglutide; titration helps minimize
- Compounded tirzepatide is not FDA-approved as a finished product
- Higher upfront price than semaglutide
Get started
See if Tirzepatide is right for you
Starts at $297 the first month.
Tirzepatide FAQ
Tirzepatide vs semaglutide — which should I choose?
Can I switch from semaglutide to tirzepatide?
Related
Compounded medications are not FDA-approved. All prescriptions require evaluation and approval by an independently licensed medical provider. Individual results vary.